These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The use of depot neuroleptics: clinical experience in the United States. Kane JM J Clin Psychiatry; 1984 May; 45(5 Pt 2):5-12. PubMed ID: 6370987 [TBL] [Abstract][Full Text] [Related]
4. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. Odejide OA; Aderounmu AF J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630 [TBL] [Abstract][Full Text] [Related]
5. [Lithium prophylaxis in schizoaffective psychoses]. Lenz G; Küfferle B; Wolf R Bibl Psychiatr; 1981; (161):45-57. PubMed ID: 7023468 [No Abstract] [Full Text] [Related]
6. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. Carpenter WT; Buchanan RW; Kirkpatrick B; Lann HD; Breier AF; Summerfelt AT Am J Psychiatry; 1999 Mar; 156(3):412-8. PubMed ID: 10080557 [TBL] [Abstract][Full Text] [Related]
8. [Schizophrenia and treatment with lithium salts. Current data from the literature]. Matot JP; Olié JP; Lôo H Encephale; 1983; 9(1):49-57. PubMed ID: 6872934 [TBL] [Abstract][Full Text] [Related]
9. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses. Roose K Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558 [TBL] [Abstract][Full Text] [Related]
10. [Treatment of schizophrenic psychoses by sustained-action neuroleptics in psychiatric outpatients' treatment (author's transl)]. Polácek J Cesk Psychiatr; 1982 Feb; 78(1):49-55. PubMed ID: 7060182 [No Abstract] [Full Text] [Related]
11. [Clinical significance of depot fluphenazine decanoate in therapy of acute psychotic disorders]. Ngui PW Seishin Shinkeigaku Zasshi; 1983; 85(9):635-9. PubMed ID: 6676769 [No Abstract] [Full Text] [Related]
12. Combination of lithium carbonate and haloperidol in schizo-affective disorder: a controlled study. Biederman J; Lerner Y; Belmaker RH Arch Gen Psychiatry; 1979 Mar; 36(3):327-33. PubMed ID: 369472 [TBL] [Abstract][Full Text] [Related]
13. Prophylactic lithium treatment: treatment response, and patient attitudes toward illness and treatment. Schmidt S; Ludwig W; Seibold S; Greil W Pharmacopsychiatry; 1988 Nov; 21(6):274-5. PubMed ID: 3244750 [No Abstract] [Full Text] [Related]
14. Adjunctive imipramine maintenance treatment in schizophrenic patients with remitted postpsychotic depression. Siris SG; Cutler J; Owen K; Mason S; Gingerich S; Lang MP Am J Psychiatry; 1989 Nov; 146(11):1495-7. PubMed ID: 2817126 [TBL] [Abstract][Full Text] [Related]
15. The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders. Mamo DC; Sweet RA; Chengappa KN; Reddy RR; Jeste DV Int J Geriatr Psychiatry; 2002 Nov; 17(11):1012-7. PubMed ID: 12404650 [TBL] [Abstract][Full Text] [Related]
16. Relapse in patients with shifting RDC diagnoses treated with lithium alone. Glazer WM; Sheard MH J Clin Psychiatry; 1982 Apr; 43(4):134-6. PubMed ID: 7068543 [TBL] [Abstract][Full Text] [Related]
18. Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study. Litman RE; Hong WW; Weissman EM; Su TP; Potter WZ; Pickar D J Clin Psychopharmacol; 1993 Aug; 13(4):264-7. PubMed ID: 8104200 [TBL] [Abstract][Full Text] [Related]
19. [Clinical picture, therapy and rehabilitation of patients with slowly-progressive (psychopath-like) schizophrenia with a loss of work capacity]. Niss AI; Shibakova TL Zh Nevropatol Psikhiatr Im S S Korsakova; 1986; 86(6):914-8. PubMed ID: 2875583 [TBL] [Abstract][Full Text] [Related]